April 8, 2008--Aradigm Corporation (OTCBB: ARDM) announced it initiated a bridging clinical trial of inhaled treprostinil utilizing its AERx Essence(R) pulmonary delivery system. The trial in healthy volunteers is being conducted in the United Kingdom to evaluate aerosol delivery by assessing lung distribution, pharmacokinetics and safety of inhaled treprostinil delivered by the AERx Essence system versus delivery with the Nebu-Tec OPTINEB*-ir nebulizer.
The latter device was used by Lung Rx, Inc. (Lung Rx), a wholly owned subsidiary of United Therapeutics Corporation, 
in the recently concluded TRIUMPH (TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension) study of inhaled treprostinil in patients with Pulmonary Arterial Hypertension (PAH)... Aradigm's Press Release -
